Prevention of venous thrombosis in surgical practice

   Currently, arterial and venous thrombosis are among the leading causes of morbidity and mortality. Anticoagulant therapy is one of the most popular approaches in practical medicine in the treatment and prevention of thrombotic conditions. The article presents the most commonly used direct-acting anticoagulants in clinical practice and their comparative clinical and pharmacological characteristics. The main recommendations for medical prevention of venous thrombosis are provided, taking into account the nature of surgical procedures and patient risk factors. The features of the use of low molecular weight heparins and unfractionated heparin against the background of regional anesthesia are given. Algorithms for interrupting antithrombotic therapy during planned and emergency surgical interventions are presented.

1. WHO. The Global Health Estimates data [electronic resource]. https://www.who.int/data/global-health-estimates. (accessed 29. 01. 2024).

2. Spyropoulos A.C., Goldin M., Giannis D., et al. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial. JAMA Intern Med, 2021, vol. 181(12), pp. 1612-1620. doi: 10.1001/jamainternmed.2021.6203

3. Gavrilenko L., Kozhanova I., Romanova I. The clinical and pharmacological characteristics of anticoagulants. Recept, 2018, vol. 21, no. 4, pp. 572-589. (in Russian).

4. Hajra A., Ujjawal A., Ghalib N., et al. Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism : A Review of Emerging Clinical Evidence. Curr Probl Cardiol, 2024, vol. 49(1Pt A), pp. 102017. doi: 10.1016/j.cpcardiol.2023.102017.

5. Feng K., Wang K., Zhou Y., et al. Non-Anticoagulant Activities of Low Molecular Weight Heparins - A Review. Pharmaceuticals (Basel), 2023, vol. 16(9), pp. 1254. doi: 10.3390/ph16091254.

6. General characteristics of the drug Fragmin [electronic resource] : Approved. by order of the Ministry of Health of the Republic Belarus, 18.08.2023, № 1803. Available at: https://www.rceth.by/NDfiles/instr/3311_98_03_08_13_16_18_23_s.pdf (accessed 29. 01. 2024). (in Russian).

7. Instructions for use of the medicinal product for medical use Fraxiparine [electronic resource] : Approved. by order of the Ministry of Health of the Republic Belarus, 27. 01. 2022 г., № 96. Available at: https://www.rceth.by/NDfiles/instr/4921_01_06_10_15_15_20_i.pdf (accessed 29. 01. 2024). (in Russian).

8. General characteristics of the drug Enoxaparin-Belmed [electronic resource] : Approved. by order of the Ministry of Health of the Republic Belarus, 30. 04. 2021., № 484. Available at: https://www.rceth.by/NDfiles/instr/21_04_3139_s.pdf (accessed 29. 01. 2024). (in Russian).

9. Instructions for medical use of the drug Arixtra [electronic resource] : Approved. by order of the Ministry of Health of the Republic. Belarus, 25. 08. 2020 г., № 899. Available at: https://www.rceth.by/NDfiles/instr/7997_06_11_15_17_20_i.pdf (accessed 29. 01. 2024). (in Russian).

10. Aursulesei V., Costache I.I. Anticoagulation in chronic kidney disease: from guidelines to clinical practice. Clin Cardiol, 2019, vol. 42(8), pp. 774-782. doi: 10.1002/clc.23196.

11. Hughes S., Szeki I., Nash M.J., Thachil J. Anticoagulation in chronic kidney disease patients – the practical aspects. Clin Kidney J, 2014, vol. 7, pp. 442-449.

12. Keo H.H., Baumann F., Diehm N., Regli C., Staub D. Rivaroxaban versus fondaparinux for thromboprophylaxis after endovenous laser ablation. J Vasc Surg Venous Lymphat Disord, 2017, vol. 5(6), pp. 817-823. doi: 10.1016/j.jvsv.2017.04.017.

13. Uthoff H., Holtz D., Broz P., Staub D., Spinedi L. Rivaroxaban for thrombosis prophylaxis in endovenous laser ablation with and without phlebectomy. J Vasc Surg Venous Lymphat Disord, 2017, vol. 5(4), pp. 515-523. doi: 10.1016/j.jvsv.2016.12.002

14. Keo H.H., Spinedi L., Staub D., et al. Duration of pharmacological thromboprophylaxis after outpatient endovenous laser ablation: a propensity score-matched analysis. Swiss Med Wkly, 2019, vol. 23, 149:w20166. doi: 10.4414/smw.2019.20166.

15. Zhang J., Lenarczyk R., Marin F., et al. The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the Eur opean Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. Europace, 2021, vol. 23(2), pp. 314-322. doi: 10.1093/europace/euaa358. PMID: 33554259.

16. Mar P.L., Familtsev D., Ezekowi tz M.D., et al. Periprocedural management of anticoagulation in patients taking novel oral anticoagulants : Review of the literature and recommendations for specific p opulations and procedures. Int J Cardiol, 2016, vol. 202, pp. 578-585. doi: 10.1016/j.ijcard.2015.09.035.

17. Gould M.K., Garcia D.A., Wren S.M., et al. Prevention of VTE in Nonorthopedic Surgical Patients. Antithrombotic Therapy and Prevention of Thrombosis, 9^th ed: American College of Chest Physici ans Evidence-Based Clinical Practice Guidelines. Chest, 2012, vol. 141(2 Suppl), pp. e227S-e277S. doi: 10.1378/chest.11-2297.